首页> 外文OA文献 >Povezanost biljega polimofizma gena HLA razreda II, CTLA-4 i PTPN22 te specifičnih autoantitijela protiv beta stanica Langerhansovih otočića s nastankom dijabetesa melitusa tipa 1 u bolesnika s autoimunom bolešću štitnjače The association of HLA class II, CTLA-4 and PTPN22 genetic polymorphisms and autoantibodies to beta Langerhans islet cells in development of type I diabetes in patients with autoimmune thyroid disease
【2h】

Povezanost biljega polimofizma gena HLA razreda II, CTLA-4 i PTPN22 te specifičnih autoantitijela protiv beta stanica Langerhansovih otočića s nastankom dijabetesa melitusa tipa 1 u bolesnika s autoimunom bolešću štitnjače The association of HLA class II, CTLA-4 and PTPN22 genetic polymorphisms and autoantibodies to beta Langerhans islet cells in development of type I diabetes in patients with autoimmune thyroid disease

机译:自身免疫性甲状腺疾病患者中HLa II类,CTLa-4和pTpN22基因多态性标志物和特异性自身抗体与1型糖尿病胰岛β细胞的关联HLa II类,CTLa-4和pTpN22基因多态性与自身抗体的关联自身免疫性甲状腺疾病患者发展为I型糖尿病的β朗格汉斯胰岛细胞

摘要

BACKGROUND: Co-occurrence of type 1 diabetes (T1D) and autoimmune thyroid diseases (AITD) in the same patient is classified as variant of autoimmune polyglandular syndrome type 3 (APS3v). At least three susceptibility genes for this syndrome have been identified, HLA class II, CTLA-4 and PTPN22 gene, all involved in T-cells antigen presentation.udSUBJECTS AND METHODS: The study comprised of 323 unrelated patients, 165 with T1D (94 with T1D alone, 71 with APS3v), aged 1.5-16.7 years, and 158 with AITD (127 with autoimmune thyroiditis, AT and 31 with Graves disease, GD), aged 4.3-25.9 years. The control group consisted of 94 unrelated healthy subjects, aged 4.7-21.5 years. Islet cell cytoplasmic (ICA), glutamic acid decarboxylase (GADA) and thyrosin phosphatase islet (IA-2) autoantibodies as well as HLA-DRB1, DQB1 genotypes, A49G and C60T polymorphisms of CTLA4 gene and R620W mutation of PTPN22 gene were analysed in all groups.udRESULTS: The prevalence of β-cell autoimmunity in patients with AITD was 10.76% (17/158), significantly higher than in control subjects (0%, 0/94; p=0.001). Higher prevalence was found in patients with AT (11.81%, 15/127) than GD (6.45%, 2/31). All three β-cell autoantibodies were found in 3 patients, and three patients were positive to two autoantibodies. All six of them developed T1D during the investigation period of 2.5 years. No difference in frequency of high or moderate risk HLA haplotypes for development of T1D in patients with AITD and β-cell autoimmunity and control subjects was found. Low risk HLA haplotypes for development of T1D were found more frequently in control subjects than in patients with AITD and islet autoimmunity (69.9% vs 31.3%, p=0.003). Disease associated G/G genotype of CTLA4 gene A49G polymorphism was significantly more common in AITD patient with islet autoimmunity than in ones without (p=0.024).udCONCLUSION: Our results indicate that patients with AITD, and in particular AT, are prone to develop β-cell autoimmunity and T1D, especially those with positive multiple islet cell autoantibodies.
机译:背景:同一患者的1型糖尿病(T1D)和自身免疫性甲状腺疾病(AITD)并发被分类为自身免疫性多腺综合征3型(APS3v)的变体。至少鉴定出了该综合征的三个易感基因,即HLA II类,CTLA-4和PTPN22基因,均与T细胞抗原呈递有关。 ud对象和​​方法:该研究由323名无关患者,165名T1D患者组成(94分别为T1D,71和APS3v,年龄1.5-16.7岁,以及158,与AITD(127是自身免疫性甲状腺炎,AT和31是Graves病,GD),年龄4.3-25.9岁。对照组由94名无关的健康受试者组成,年龄为4.7-21.5岁。分析了所有细胞的胰岛细胞质(ICA),谷氨酸脱羧酶(GADA)和甲状腺素磷酸酶胰岛(IA-2)自身抗体以及CTLA4基因的HLA-DRB1,DQB1基因型,A49G和C60T多态性以及PTPN22基因的R620W突变。结果:AITD患者的β细胞自身免疫患病率为10.76%(17/158),明显高于对照组(0%,0/94; p = 0.001)。发现AT患者(11.81%,15/127)的患病率高于GD(6.45%,2/31)。在3例患者中发现了所有3种β细胞自身抗体,其中3例患者对2例自身抗体呈阳性。他们全部六个人在2.5年的调查期内都发展了T1D。在AITD和β细胞自身免疫性疾病患者和对照组中,发现高危或中危HLA单倍型发生T1D的频率没有差异。与AITD和胰岛自身免疫性疾病的患者相比,在对照受试者中发现发生T1D的低风险HLA单倍型更为常见(69.9%比31.3%,p = 0.003)。结论CTLA4基因A49G多态性与疾病相关的G / G基因型在患有胰岛自身免疫性疾病的AITD患者中比没有胰岛自身免疫性疾病的患者更为常见(p = 0.024)。 ud结论:我们的结果表明,AITD患者,特别是AT患者,容易发生发展β细胞自身免疫和T1D,尤其是那些具有多个胰岛细胞自身抗体阳性的人。

著录项

  • 作者

    Rojnić Putarek Nataša;

  • 作者单位
  • 年度 2015
  • 总页数
  • 原文格式 PDF
  • 正文语种 en
  • 中图分类

相似文献

  • 外文文献
  • 中文文献

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号